TY  - JOUR
AU  - Fazekas, Tamás
AU  - Miszczyk, Marcin
AU  - Giesen, Alexander
AU  - Kói, Tamás
AU  - Zattoni, Fabio
AU  - Rodriguez-Sanchez, Lara
AU  - Yanagisawa, Takafumi
AU  - Matsukawa, Akihiro
AU  - Szarvas, Tibor
AU  - Kryst, Piotr
AU  - Rivas, Juan Gómez
AU  - Merseburger, Axel S
AU  - Santis, Maria De
AU  - Joniau, Steven
AU  - Briganti, Alberto
AU  - Marra, Giancarlo
AU  - Nyirády, Péter
AU  - Gandaglia, Giorgio
AU  - Shariat, Shahrokh F
AU  - Rajwa, Pawel
TI  - Androgen Receptor Pathway Inhibitor Monotherapy in Prostate Cancer: Safety, Oncologic Outcomes, and Quality of Life-A Systematic Review and Meta-analysis.
JO  - European urology focus
VL  - nn
SN  - 2405-4569
CY  - Amsterdam
PB  - Elsevier
M1  - DKFZ-2025-01061
SP  - nn
PY  - 2025
N1  - epub
AB  - Androgen receptor pathway inhibitors (ARPIs) as monotherapy are studied increasingly across prostate cancer disease states. We aimed to evaluate the safety, oncologic efficacy, and quality of life (QoL) of ARPI monotherapy as compared with ARPI + androgen deprivation therapy (ADT) and ADT alone.PubMed/Medline, Embase, and Cochrane/Central were queried through June 2024 for clinical trials. The primary outcomes were the rates of adverse events (AEs) presented as risk ratios (RRs); the secondary outcomes included efficacy and QoL.We synthesized data from 2015 men, retrieved from 17 studies. The incidence of any AEs was similar between patients on ARPIs, ARPI + ADT (RR: 1.01, 95
KW  - Abiraterone (Other)
KW  - Androgen deprivation therapy (Other)
KW  - Androgens (Other)
KW  - Apalutamide (Other)
KW  - Darolutamide (Other)
KW  - Enzalutamide (Other)
KW  - Testosterone (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:40404535
DO  - DOI:10.1016/j.euf.2025.05.006
UR  - https://inrepo02.dkfz.de/record/301540
ER  -